Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

被引：16
|
作者：
Sandoval-Sus, Jose D. [1 ]
Chavez, Julio C. [2 ]
Dalia, Samir [3 ]
Bello, Celeste M. [4 ]
Shah, Bijal D. [2 ]
Ho, Viet Q. [2 ]
Nodzon, Lisa [4 ]
Kharfan-Dabaja, Mohamed A. [5 ]
Sotomayor, Eduardo M. [6 ]
Sokol, Lubomir [7 ]
Pinilla-Ibarz, Javier [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA
[3] Mercy Clin Oncol & Hematol, Joplin, MO USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA
[6] George Washington Univ, Ctr Canc, Div Hematol Oncol, Washington, DC USA
[7] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2945.2945
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
    Rigolin, Gian Matteo
    Cavazzini, Francesco
    Piciocchi, Alfonso
    Arena, Valentina
    Visentin, Andrea
    Reda, Gianluigi
    Zamprogna, Giulia
    Cibien, Francesca
    Vitagliano, Orsola
    Coscia, Marta
    Farina, Lucia
    Gaidano, Gianluca
    Murru, Roberta
    Varettoni, Marzia
    Paolini, Rossella
    Sportoletti, Paolo
    Pietrasanta, Daniela
    Molinari, Anna Lia
    Quaglia, Francesca M.
    Laurenti, Luca
    Marasca, Roberto
    Marchetti, Monia
    Mauro, Francesca R.
    Crea, Enrico
    Vignetti, Marco
    Gentile, Massimo
    Montillo, Marco
    Foa, Robin
    Cuneo, Antonio
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (03) : 326 - 335
  • [42] Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation
    Barrientos, Jacqueline C.
    Kaur, Manmeen
    Mark, Alexis
    Chung, Jaewon
    Driscoll, Nancy
    Bender, Alison
    Rai, Kanti R.
    BLOOD, 2015, 126 (23)
  • [43] Rapid Progression of Disease Following Ibrutinib Discontinuation in Patients With Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 4 - 6
  • [44] Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials
    Swarup, Sriman
    Quick, Donald P.
    Sultan, Anita
    D'Cunha, Nicholas
    Htut, Thura Win
    Hlaing, Pwint Phyu
    Sharma, Upama
    Adhikari, Nimesh
    Aung, Ye
    Han, Myat Min
    Myat, Yin Mon
    Hardwicke, Fred
    Tijani, Lukman
    Thein, Kyaw Zin
    BLOOD, 2019, 134
  • [45] A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
    Pooler, Darcy B.
    Ness, Dylan B.
    Danilov, Alexey V.
    Labrie, Bridget M.
    Tosteson, Tor D.
    Eastman, Alan
    Lewis, Lionel D.
    Lansigan, Frederick
    EJHAEM, 2022, 3 (04): : 1445 - 1448
  • [46] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [47] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [48] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [49] Prognostic Role of Beta-2 Microglobulin in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 12 - 13
  • [50] Lenalidomide active in patients with refractory or relapsed chronic lymphocytic leukemia
    Nature Clinical Practice Oncology, 2007, 4 (3): : 143 - 143
12345